U.S. Markets open in 6 hrs 6 mins

Ensign Group to Spin Off Home Health & Hospice Business

Zacks Equity Research

The Ensign Group, Inc. ENSG recently announced that its board of directors has authorized the separation of its home health and hospice business and also all its senior living operations from the parent company into a separate publicly traded entity. The same is subject to certain closing conditions.

On the closure of this spin-off, there will be two different companies, namely The Ensign Group, Inc. that will consist of the transitional and skilled services, rehabilitative care services, healthcare campuses, post-acute-related new business endeavors and real estate investments, and The Pennant Group, Inc., which will comprise the company’s home health and hospice business line and substantially, all its senior living operations.

Ensign Group’s stockholders as of Sep 20, 2019 will get shares of the Pennant common stock on a pro rata basis, effective Oct 1, 2019. They will get a share of Pennant for every two shares owned in the company. Moreover, it is to be noted that no fractional shares will be distributed. A cash payment will be given in place of the same.

With this spin-off, Ensign Group is expected to unlock more earnings prospects and enhance its shareholder value. The company hopes that it will be able to add value to its home health, senior living and hospice business line from this spin-off like it had earlier gained traction from its 2014 CareTrust spin-off.

The home and hospice business has been contributing to the bottom line over the last few quarters, which is evident from its 20% and 22% year-over-year growth in revenues during 2018 and the first half of 2019, respectively.

Management also opines that Ensign Group will not slow down its acquisition activity because of this spin-off. It will continue to seek transactions to acquire real estate and lease both well-performing and struggling skilled nursing, assisted living and other healthcare related businesses in the new and the existing markets.

Shares of this Zacks Rank #2 (Buy) company have rallied 26% against its industry’s decline of 2.4% in the past year.



Other Key Picks

Investors interested in the medical sector can also take a look at some other top-ranked stocks like Molina Healthcare, Inc. MOH, Lannett Co Inc LCI and FibroGen, Inc FGEN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Molina Healthcare provides managed health care services under the Medicaid and Medicare programs, and through the state insurance marketplaces. The company managed to pull off average four-quarter positive surprise of 66.9%.

Lannett Company works with generic versions of brand pharmaceutical products in the United States. In the last four quarters, the company delivered average beat of 30.6%.

FibroGen discovers, develops and commercializes therapeutics to treat serious unmet medical requirements. In the trailing four quarters, the company came up with average beat of 346.6%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
FibroGen, Inc (FGEN) : Free Stock Analysis Report
 
Lannett Co Inc (LCI) : Free Stock Analysis Report
 
Molina Healthcare, Inc (MOH) : Free Stock Analysis Report
 
The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research